Summary:
The focus of this book is on how the U.S. FDA will approve biosimilar drugs, as learned from recent approvals by the FDA. Understanding the limitations of the statutory limits and non-inferiority testing are presented as tools to obviate patient trials and minimize testing of immunogenicity. An in-depth scientific, mathematical and statistical view of the tools required to establish biosimilarity of biological drugs of different complexity -- a must for every developer of biosimilars.
Features:
First comprehensive analysis based on new guidelines and approval packages of several biosimilars
Presents the first approach to challenge FDA in reducing or eliminating any testing in patients.
Provides a comprehensive understanding of the U.S. statutory requirements vis-a-vis the regulatory guidelines
Provides model CQA and Analytical Similarity testing protocols for cytokines and monoclonal antibodies
Allow creation of a fast-to-market pathway to develop biosimilars
"synopsis" may belong to another edition of this title.
Sarfaraz K. Niazi Ph.D, is Adjunct Professor at the faculty of University of Houston as well Chairman and President of Therapeutic Proteins Inc.
"About this title" may belong to another edition of this title.
Shipping:
FREE
Within U.S.A.
Book Description Condition: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. Seller Inventory # ABEOCT23-138949
Book Description Condition: New. pp. 432. Seller Inventory # 26374165178
Book Description Condition: New. Seller Inventory # 25818757-n
Book Description Condition: New. pp. 432. Seller Inventory # 372961637
Book Description Hardcover. Condition: new. Seller Inventory # 9781498750394
Book Description Hardcover. Condition: New. Brand New! This item is printed on demand. Seller Inventory # VIB1498750397
Book Description Condition: New. Seller Inventory # 25818757-n
Book Description Gebunden. Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Sarfaraz K. Niazi Ph.D, is Adjunct Professor at the faculty of University of Houston as well Chairman and President of Therapeutic Proteins Inc.First comprehensive analysis based on new guidelines and approval packages of . Seller Inventory # 596130894
Book Description HRD. Condition: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Seller Inventory # L1-9781498750394
Book Description Hardcover. Condition: Brand New. 397 pages. 10.25x7.25x1.00 inches. In Stock. Seller Inventory # __1498750397